Terms: = Head and neck cancer AND GRIN2A, Q12879, 2903, ENSG00000183454, NMDAR2A, NR2A AND Treatment
4 results:
1. [Clinicopathological features of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma].
Zhu M; Li J; Zheng WH; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2023 Aug; 52(8):820-826. PubMed ID: 37527987
[No Abstract] [Full Text] [Related]
2. Symptom burden among head and neck cancer patients in the first year after diagnosis: Association with primary treatment modality.
Allen-Ayodabo CO; Eskander A; Davis LE; Zhao H; Mahar AL; Karam I; Singh S; Gupta V; Bubis LD; Moody L; Barbera L; Coburn NG
Oral Oncol; 2019 Dec; 99():104434. PubMed ID: 31630058
[TBL] [Abstract] [Full Text] [Related]
3. Cytogenetic and dosimetric effects of (131)I in patients with differentiated thyroid carcinoma: comparison between stimulation with rhTSH and thyroid hormone withdrawal treatments.
da Silva MA; Valgôde FG; Gonzalez JA; Yoriyaz H; Guimarães MI; Ribela MT; Buchpiguel CA; Bartolini P; Okazaki K
Radiat Environ Biophys; 2016 Aug; 55(3):317-28. PubMed ID: 27013085
[TBL] [Abstract] [Full Text] [Related]
4. Comparative dosimetric study of two strategies of intensity-modulated radiotherapy in nasopharyngeal cancer.
Chen SW; Yang SN; Liang JA; Shiau AC; Lin FJ
Med Dosim; 2005; 30(4):219-27. PubMed ID: 16275564
[TBL] [Abstract] [Full Text] [Related]
